Blis Technologies forecasts 75% gain in annual sales

By Jonathan Underhill July 31 (BusinessDesk) - Blis Technologies, the NZX-listed biotech company, said sales will rise as much as 75 percent, helped by demand in Europe, North America and in New Zealand. Sales in the year ending March 31, 2016, are expected to "comfortably exceed $4.5 million," chief executive Barry Richardson told shareholders at their annual meeting. Blis would likely report  "a small operating deficit before interest, tax, depreciation & amortisation" for the year. First quarter sales doubled to $945,000, he said. "...